The House of Representatives is expected to grant final approval to the COVID-19 relief bill by Tuesday; FDA probes major baby food companies selling products containing unsafe levels of toxic heavy metals; FDA issues emergency authorization for novel test to detect past COVID-19 infection.
This past Saturday, the Senate passed the $1.9 trillion coronavirus relief package, sending it back to the House of Representatives for final approval, which is expected by Tuesday. Reported by CNBC, the bill is expected to be signed into law by President Joe Biden prior to the March 14 deadline, when enhanced federal unemployment benefits are set to expire. In addition to direct payments of $1400 to most Americans, the bill would provide a $300 weekly increase to jobless benefits into September and an expansion of the child tax credit for 1 year.
Reported by POLITICO, the FDA plans to investigate reports of toxic heavy metals commonly found in baby food. Spotlighted by a report released last month by the House Oversight subcommittee, findings indicated that major baby food companies were selling products that their own internal testing showed contained arsenic, lead, and cadmium at levels that health experts would consider unsafe for infants. As the FDA begins their investigation, the agency told baby food makers they are expected to actively reduce heavy metal levels in their products flagged by internal food safety controls.
The FDA issued an emergency authorization for a first-of-its-kind-test developed by Seattle-based Adaptive Biotechnologies that leverages machine learning to detect past COVID-19 infections. Unlike prior tests that assessed levels of coronavirus antibodies, the T-Detect COVID test looks for evidence of past infection in the body’s adaptive immune system, particularly T cells, that function by helping the body remember past viruses.
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
For Neuromuscular Disease Community, an Era of Opportunities and Threats
March 17th 2025Robert Califf, MD, former commissioner of the FDA, delivered a keynote address at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference that highlighted the enormous opportunities for progress in neuromuscular disease care amid a changing policy environment.
Read More
The Impact of Cost Sharing on High-Value Care
March 14th 2025Michael Chernew, PhD, professor of health care policy and director of the Healthcare Markets and Regulation Lab, Harvard Medical School, shares how cost-sharing policies shape access to critical health care services and influence value-based insurance design.
Read More
Oz Confirmation Hearing Probes Vision for Medicaid but Coalesces Around Well-Being
March 14th 2025Mehmet Oz, MD, the nominee to lead CMS under the Trump administration, testified in a confirmation hearing before the Senate Finance Committee, where he found common ground on improving outcomes through healthier lifestyle choices but encountered repeated questions on potential Medicaid cuts.
Read More